Loading...

ALKS ALKERMES PLC Other Situations 8-K Filing

LKRM

LKS

ALKERMES PLC

(ALKS)

2025 8-K

Acquisition Completed

Corporate Presentation Update

FDA Breakthrough Designation

Increased Acquisition Offer

Positive Study Results

Financial Update

Acquisition Announcement

Legal Action Update

Leadership Change

Safety Study Results

Financial Statements

New Product Launches

Elections of Directors

Financial Statements

Management Change

Financial Results

Corporate Presentation

Credit Agreement Termination

Corporate Presentation

Financial Results

Financial Results Announcement

Shareholder Approval and El...

Earnings Reports

Positive Results Announcement

Appointment of Director

Financial Results Announcement

Appointment of Interim Offi...

Presentation at Conference

Retirement of Director

Agreements with Mural Oncology

Separation of Oncology Busi...

Other Special Situation

Financial Results Announcement

Financial Results Announcement

Debt Restructuring

Earnings Reports

Arbitration Award

Financial Results Announcement

Notice of Director Nominations

Presentation at Conference

Arbitration Interim Award

External Links:

On November 12, 2025, Alkermes plc announced successful topline results from its Vibrance-2 phase 2 study for alixorexton in treating narcolepsy type 2, during an investor webcast.

AI Assistant

ALKERMES PLC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.